Last reviewed · How we verify
Open Label Treatment Access: Maraviroc — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Open Label Treatment Access: Maraviroc (Open Label Treatment Access: Maraviroc) — ViiV Healthcare.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Open Label Treatment Access: Maraviroc TARGET | Open Label Treatment Access: Maraviroc | ViiV Healthcare | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Open Label Treatment Access: Maraviroc CI watch — RSS
- Open Label Treatment Access: Maraviroc CI watch — Atom
- Open Label Treatment Access: Maraviroc CI watch — JSON
- Open Label Treatment Access: Maraviroc alone — RSS
Cite this brief
Drug Landscape (2026). Open Label Treatment Access: Maraviroc — Competitive Intelligence Brief. https://druglandscape.com/ci/open-label-treatment-access-maraviroc. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab